About: Copper (64Cu) oxodotreotide

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Copper (64Cu) oxodotreotide or Copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults. Common side effects include nausea, vomiting and flushing. It was approved for medical use in the United States in September 2020.

Property	Value
dbo:abstract	Copper (64Cu) oxodotreotide or Copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults. Common side effects include nausea, vomiting and flushing. It was approved for medical use in the United States in September 2020. (en)
dbo:alternativeName	Detectnet (en)
dbo:casNumber	1426155-87-4
dbo:fdaUniiCode	N3858377KC
dbo:inn	Copper (64Cu) oxodotreotide
dbo:kegg	D11882
dbo:pubchem	124220636
dbo:thumbnail	wiki-commons:Special:FilePath/Copper_(64Cu)_oxodotreotide.svg?width=300
dbo:wikiPageExternalLink	https://www.curiumpharma.com/wp-content/uploads/2020/08/SDS-US-copper-Cu-64-dotatate-injection_.pdf https://druginfo.nlm.nih.gov/drugportal/name/copper%20dotatate%20cu-64
dbo:wikiPageID	65239613 (xsd:integer)
dbo:wikiPageLength	6692 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1120345182 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Somatostatin_receptor dbr:Copper-64 dbc:Copper_complexes dbc:DOTA_(chelator)_derivatives dbc:Radiopharmaceuticals dbc:Orphan_drugs dbr:DOTA-TATE dbr:Food_and_Drug_Administration dbr:Positron_emission_tomography dbr:Intravenous dbr:PET_radiotracer dbr:Neuroendocrine_tumors
dbp:atcPrefix	None (en)
dbp:c	65 (xsd:integer)
dbp:casNumber	1426155 (xsd:integer)
dbp:cu	1 (xsd:integer)
dbp:dailymedid	Detectnet (en)
dbp:h	88 (xsd:integer)
dbp:inn	Copper oxodotreotide (en)
dbp:iupacName	2 (xsd:integer)
dbp:kegg	D11882 (en)
dbp:legalUs	Rx-only (en)
dbp:n	14 (xsd:integer)
dbp:o	19 (xsd:integer)
dbp:pregnancyUs	N (en)
dbp:pubchem	124220636 (xsd:integer)
dbp:routesOfAdministration	dbr:Intravenous
dbp:s	2 (xsd:integer)
dbp:smiles	CCO.[Cu+2] (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	IJRLLVFQGCCPPI-NVGRTJHCSA-L (en)
dbp:tradename	Detectnet (en)
dbp:unii	N3858377KC (en)
dbp:width	300 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Cite_web dbt:Diagnostic_radiopharmaceuticals dbt:Infobox_drug dbt:Pharma-stub dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_American_English dbt:Use_dmy_dates
dcterms:subject	dbc:Copper_complexes dbc:DOTA_(chelator)_derivatives dbc:Radiopharmaceuticals dbc:Orphan_drugs
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Copper (64Cu) oxodotreotide or Copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults. Common side effects include nausea, vomiting and flushing. It was approved for medical use in the United States in September 2020. (en)
rdfs:label	(64Cu)-oxodotreotid (cs) Copper (64Cu) oxodotreotide (en)
owl:sameAs	wikidata:Copper (64Cu) oxodotreotide dbpedia-cs:Copper (64Cu) oxodotreotide https://global.dbpedia.org/id/FVdzo
prov:wasDerivedFrom	wikipedia-en:Copper_(64Cu)_oxodotreotide?oldid=1120345182&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Copper_(64Cu)_oxodotreotide.svg
foaf:isPrimaryTopicOf	wikipedia-en:Copper_(64Cu)_oxodotreotide
is dbo:wikiPageRedirects of	dbr:Copper_Cu_64_dotatate dbr:Detectnet
is dbo:wikiPageWikiLink of	dbr:Copper_Cu_64_dotatate dbr:Detectnet dbr:DOTA-TATE
is rdfs:seeAlso of	dbr:Copper-64
is foaf:primaryTopic of	wikipedia-en:Copper_(64Cu)_oxodotreotide